Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. / Yan, H; Guo, YH; Zhang, P; Zu, LY; Dong, XY; Chen, L; Tian, JW; Fan, Xiaolong; Wang, NP; Wu, XB; Gao, W.

I: Biochemical and Biophysical Research Communications, Vol. 336, Nr. 1, 2005, s. 287-298.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Yan, H ; Guo, YH ; Zhang, P ; Zu, LY ; Dong, XY ; Chen, L ; Tian, JW ; Fan, Xiaolong ; Wang, NP ; Wu, XB ; Gao, W. / Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors. I: Biochemical and Biophysical Research Communications. 2005 ; Vol. 336, Nr. 1. s. 287-298.

RIS

TY - JOUR

T1 - Superior neovascularization and muscle regeneration in ischemic skeletal muscles following VEGF gene transfer by rAAV1 pseudotyped vectors

AU - Yan, H

AU - Guo, YH

AU - Zhang, P

AU - Zu, LY

AU - Dong, XY

AU - Chen, L

AU - Tian, JW

AU - Fan, Xiaolong

AU - Wang, NP

AU - Wu, XB

AU - Gao, W

PY - 2005

Y1 - 2005

N2 - Recombinant adeno-associated virus serotype 2 (rAAV2) vector has been widely employed for gene therapy. Recent progress suggests that the new serotypes of AAV showed a better performance than did AAV2 in normal tissues. Here, we evaluate the potential role of human vascular endothelial growth factor (VEGF) gene transfer using rAAV vector pseudotyped with serotype I capsid proteins (rAAV1) in the treatment of muscle ischemia. In ischemic skeletal muscles, the rAAV1-LacZ vector allowed higher level, broader distribution, and long-lasting gene expression compared with the rAAV2-LacZ vector. Muscle VEGF165 production following the rAAV1-VEGF165 vector injection was 5-10 times higher than that following the rAAV2-VEGF165 vector injection. VEGF165 production mediated by the rAAV1-VEGF165 vector stimulated a large set of neovascularization with relatively mature vascular structures and enhanced muscle regeneration in the ischemic skeletal muscles. Thus, the rAAV1-NEGF165 vector mediated gene transfer may be a therapeutic approach to peripheral vascular diseases.

AB - Recombinant adeno-associated virus serotype 2 (rAAV2) vector has been widely employed for gene therapy. Recent progress suggests that the new serotypes of AAV showed a better performance than did AAV2 in normal tissues. Here, we evaluate the potential role of human vascular endothelial growth factor (VEGF) gene transfer using rAAV vector pseudotyped with serotype I capsid proteins (rAAV1) in the treatment of muscle ischemia. In ischemic skeletal muscles, the rAAV1-LacZ vector allowed higher level, broader distribution, and long-lasting gene expression compared with the rAAV2-LacZ vector. Muscle VEGF165 production following the rAAV1-VEGF165 vector injection was 5-10 times higher than that following the rAAV2-VEGF165 vector injection. VEGF165 production mediated by the rAAV1-VEGF165 vector stimulated a large set of neovascularization with relatively mature vascular structures and enhanced muscle regeneration in the ischemic skeletal muscles. Thus, the rAAV1-NEGF165 vector mediated gene transfer may be a therapeutic approach to peripheral vascular diseases.

KW - endothelial growth factor

KW - vascular

KW - gene delivery

KW - serotype 1

KW - adeno-associated virus

KW - muscle

KW - ischemia

U2 - 10.1016/j.bbrc.2005.08.066

DO - 10.1016/j.bbrc.2005.08.066

M3 - Article

VL - 336

SP - 287

EP - 298

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 1090-2104

IS - 1

ER -